We collaborate to understand underlying biology and develop tailored approaches for disease target validation. Using high-content methods like multiparameter flow cytometry and immunohistochemistry, we assess target expression in fresh and frozen tissues and cells from healthy donors and patient populations, cryopreserved PBMCs, recallable blood donors, and a vast collection of immortalised cell lines. Our world-class team of immune cell experts applies their expertise to hypothesis testing of new targets using in vitro immunology models. We tailor services to address the underlying biology, employing complex models built with our expertise in T cells, Tregs, NK cells, DCs, B cells, neutrophils, macrophages, and PBMC/whole blood.

We use surrogate molecules and engineered approaches to explore target function and gain clarity. Custom-designed signalling reporter cells and knockout engineered cell systems help delineate converging signalling pathways and achieve greater resolution. Partner with us to advance your therapeutic development with precision and efficiency. 

With extensive experience in bioanalytical assay design, immunology, cellular and molecular biology, we create platform screening systems tailored to your needs. Our multi-tier lead selection process focuses on binding, functionality and disease translation. We utilise ELISA, SPR, flow cytometry, kinetic analysis and immune cell functional assays to select and validate leads with confidence.